CD38 and Miyoshi myopathy: MM cell markers, including BCMA and CD38, were also coexpressed on normal B lymphocytes; therefore, anti-BCMA antibody-based immunotherapy could also result in B-cell aplasia, neutropenia, and immunosuppression, leading to increased infection risks.